Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum‐based regimen and disease at baseline on efficacy and safety-Reference-Cited by-同舟云学术

Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum‐based regimen and disease at baseline on efficacy and safety

Published:2021-09-21 Issue:20 Volume:10 Page:7162-7173
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Oaknin Ana¹,Oza Amit M.²,Lorusso Domenica³,Aghajanian Carol⁴,Dean Andrew⁵,Colombo Nicoletta⁶,Weberpals Johanne I.⁷^ORCID,Clamp Andrew R.⁸,Scambia Giovanni⁹^ORCID,Leary Alexandra¹⁰,Holloway Robert W.¹¹,Amenedo Gancedo Margarita¹²,Fong Peter C.¹³,Goh Jeffrey C.¹⁴,O’Malley David M.¹⁵,Armstrong Deborah K.¹⁶,Banerjee Susana¹⁷,García‐Donas Jesus¹⁸,Swisher Elizabeth M.¹⁹,Cameron Terri²⁰,Maloney Lara²¹,Goble Sandra²²,Ledermann Jonathan A.²³,Coleman Robert L.²⁴^ORCID

Affiliation:

1. Gynaecologic Cancer Programme Vall d’Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d’Hebron, Vall d’Hebron Barcelona Hospital Campus Barcelona Spain

2. Division of Medical Oncology and Hematology Princess Margaret Cancer Centre University Health Network Toronto Canada

3. Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies and Gynecologic Oncology Unit Fondazione IRCCS, Istituto Nazionale dei Tumori Milan Italy

4. Department of Medicine Memorial Sloan Kettering Cancer Center New York New York USA

5. Oncology St John of God Subiaco Hospital Subiaco Western Australia Australia

6. Gynecologic Cancer Program University of Milan‐Bicocca and European Institute of Oncology IRCCS Milan Italy

7. Division of Gynecologic Oncology Ottawa Hospital Research Institute Ottawa Canada

8. Department of Medical Oncology The Christie NHS Foundation Trust and University of Manchester Manchester United Kingdom

9. Gynecologic Oncology Unit Fondazione Policlinico Universitario A. Gemelli IRCCS and Scientific Directorate Rome Italy

10. Gynecological Unit, Gustave Roussy Cancer Center INSERM U981, and Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens Villejuif France

11. Gynecologic Oncology AdventHealth Cancer Institute Orlando Florida USA

12. Medical Oncology Department Oncology Center of Galicia, Doctor Camilo Veiras La Coruña Spain

13. Medical Oncology Department Auckland City Hospital, and University of Auckland Auckland New Zealand

14. Department of Oncology, Cancer Care Services Royal Brisbane and Women’s Hospital, and University of Queensland Herston Queensland Australia

15. Division of Gynecologic Oncology The Ohio State University, James Cancer Center Columbus Ohio USA

16. Oncology, Gynecology and Obstetrics Johns Hopkins Kimmel Cancer Center Baltimore Maryland USA

17. Gynaecology Unit The Royal Marsden NHS Foundation Trust and Institute of Cancer Research London United Kingdom

18. Division of Medical Oncology HM Hospitales—Centro Integral Oncológico Hospital de Madrid Clara Campal Madrid Spain

19. Division of Gynecologic Oncology University of Washington Seattle Washington USA

20. Clinical Science Clovis Oncology UK Ltd Cambridge United Kingdom

21. Clinical Development Clovis Oncology, Inc Boulder Colorado USA

22. Biostatistics Clovis Oncology, Inc Boulder Colorado USA

23. Department of Oncology University College London (UCL) Cancer Institute and UCL Hospitals London United Kingdom

24. Department of Gynecologic Oncology and Reproductive Medicine University of Texas MD Anderson Cancer Center Houston Texas USA

Funder

Memorial Sloan-Kettering Cancer Center

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.4260

Reference19 articles.

1. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®).Ovarian cancer including fallopian tube cancer and primary peritoneal cancer (version 1.2021). Accessed May 7 2021.https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf

2. ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

3. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy

5. Maintenance treatment of recurrent ovarian cancer: Is it ready for prime time?

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of PARP inhibitors for maintenance treatment of ovarian cancer, regardless of BRCA or HRD status: a comprehensive updated meta-analysis;Journal of Obstetrics and Gynaecology;2023-02-02

2. Therapeutic Targeting of DNA Damage Repair in the Era of Precision Oncology and Immune Checkpoint Inhibitors;Journal of Immunotherapy and Precision Oncology;2022-12-02

3. Tumor BRCA Testing in Epithelial Ovarian Cancers: Past and Future—Five-Years’ Single-Institution Experience of 762 Consecutive Patients;Cancers;2022-03-23